Access Biotechnology Team
Photo of Dan Becker, Managing Director at Access Biotechnology
Dan Becker
Access Biotechnology·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Mateo (CA), Investors in New York (NY)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in New York City (Other Lists), Investors in BioTech (Seed), Investors in San Francisco Bay Area (Other Lists)
to see your intro paths to Dan
Photo of Christine Borowski, Vice President at Access Biotechnology
Christine Borowski
Access Biotechnology·Vice President
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York City
Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Therapeutics (Seed), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in New York City (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Seed)
to see your intro paths to Christine
Photo of Liam Ratcliffe, Investor at Access Biotechnology
Liam Ratcliffe
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists)
to see your intro paths to Liam